Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer

被引:13
作者
Roberts, Megan C. [1 ]
Kurian, Allison W. [2 ]
Petkov, Valentina I. [1 ]
机构
[1] NCI, Bethesda, MD 20892 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 06期
关键词
RECURRENCE SCORE ASSAY; CLINICAL DECISION-MAKING; ONCOTYPE DX; TREATMENT RECOMMENDATIONS; IMPACT; CHEMOTHERAPY;
D O I
10.6004/jnccn.2018.7266
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study assessed uptake of the Oncotype DX 21-gene assay over time and characterized which sociodemographic and clinical factors are associated with test uptake among women with lymph node-positive (LN+), hormone receptor-positive, HER2-negative breast cancer. Methods: Invasive breast cancer cases diagnosed in 2010 through 2013 were included from a SEER database linked to 21-gene assay results performed at Genomic Health's Clinical Laboratory. Factors associated with 21-gene assay uptake were identified using a multivariable logistic regression model. Results: Uptake of the 21-gene assay increased over time and differed by race, socioeconomic status (SES), and age. In the multivariable model, when clinical and SES variables were controlled for, racial differences in test uptake were no longer observed. Private insurance status was associated with higher odds of 21-gene assay uptake (Medicaid vs private insurance: adjusted odds ratio, 0.86; P=.02), and high area-level SES was associated with an increased odds of uptake (quintile 5 vs 1: adjusted odds ratio, 1.6; P<.001). Demographic factors such as age and marital status influenced test uptake, and use varied greatly by geographic region. Uptake of the 21-gene assay increased over time and preceded the assay's inclusion in the NCCN Guidelines for LN+ breast cancer. Differences in uptake by race, SES, and age have persisted over time. However, when clinical and SES variables were controlled for, racial differences in assay uptake were no longer observed. Socioeconomic variables, such as health insurance type and area-level SES, were associated with assay uptake. Conclusions: Future research should continue to document practice patterns related to the 21-gene assay. Given variation in testing associated with area-level SES, insurance coverage, and geographic region, interventions to understand and reduce differential uptake are needed to ensure equitable access to this genomic test.
引用
收藏
页码:662 / 668
页数:7
相关论文
共 50 条
[31]   Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer [J].
Breaux, Andrea ;
Turner, Bradley ;
Wu, Xiaoyong ;
Rai, Shesh N. ;
Riley, Elizabeth C. ;
Mandadi, Mounika ;
Sanders, Mary Ann .
CLINICAL BREAST CANCER, 2019, 19 (01) :E261-E269
[32]   Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer [J].
Ma, Sung Jun ;
Gill, Jasmin ;
Yendamuri, Keerti ;
Chatterjee, Udit ;
Waldman, Olivia ;
Dunne-Jaffe, Cynthia ;
Fekrmandi, Fatemeh ;
Shekher, Rohil ;
Iovoli, Austin ;
Yao, Song ;
Oladeru, Oluwadamilola T. ;
Singh, Anurag K. .
BMC CANCER, 2023, 23 (01)
[33]   Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer [J].
Sung Jun Ma ;
Jasmin Gill ;
Keerti Yendamuri ;
Udit Chatterjee ;
Olivia Waldman ;
Cynthia Dunne-Jaffe ;
Fatemeh Fekrmandi ;
Rohil Shekher ;
Austin Iovoli ;
Song Yao ;
Oluwadamilola T. Oladeru ;
Anurag K. Singh .
BMC Cancer, 23
[34]   Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer [J].
Yu, Jing ;
Lin, Caijin ;
Huang, Jiahui ;
Hong, Jin ;
Gao, Weiqi ;
Zhu, Siji ;
Lin, Lin ;
Chen, Xiaosong ;
Huang, Ou ;
He, Jianrong ;
Zhu, Li ;
Chen, Weiguo ;
Li, Yafen ;
Wu, Jiayi ;
Shen, Kunwei .
BMC CANCER, 2021, 21 (01)
[35]   Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer [J].
Makower, Della ;
Lin, Juan ;
Xue, Xiaonan ;
Sparano, Joseph A. .
NPJ BREAST CANCER, 2021, 7 (01)
[36]   Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database [J].
Roberts, Megan C. ;
Miller, Dave P. ;
Shak, Steven ;
Petkov, Valentina I. .
BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (02) :303-310
[37]   Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial [J].
Abdou, Yara ;
Barlow, William E. ;
Gralow, Julie R. ;
Meric-Bernstam, Funda ;
Albain, Kathy S. ;
Hayes, Daniel F. ;
Lin, Nancy U. ;
Perez, Edith A. ;
Goldstein, Lori J. ;
Chia, Stephen K. L. ;
Dhesy-Thind, Sukhbinder ;
Rastogi, Priya ;
Alba, Emilio ;
Delaloge, Suzette ;
Schott, Anne F. ;
Shak, Steven ;
Sharma, Priyanka ;
Lew, Danika L. ;
Miao, Jieling ;
Unger, Joseph M. ;
Tripathy, Debasish ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos ;
Kalinsky, Kevin .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2025,
[38]   21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy [J].
Mamounas, Eleftherios P. ;
Liu, Qing ;
Paik, Soonmyung ;
Baehner, Frederick L. ;
Tang, Gong ;
Jeong, Jong-Hyeon ;
Kim, S. Rim ;
Butler, Steven M. ;
Jamshidian, Farid ;
Cherbavaz, Diana B. ;
Sing, Amy P. ;
Shak, Steven ;
Julian, Thomas B. ;
Lembersky, Barry C. ;
Wickerham, D. Lawrence ;
Costantino, Joseph P. ;
Wolmark, Norman .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (04)
[39]   Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer [J].
Partin, Jessica F. ;
Mamounas, Eleftherios P. .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (12) :3399-3406
[40]   Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer [J].
Koh, Minji ;
Jung, Jinhong ;
Kim, Su Ssan ;
Do Ahn, Seung ;
Choi, Eun Kyung ;
Chung, Il Yong ;
Lee, Jong Won ;
Kim, Sung-Bae ;
Jeong, Jae Ho .
BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (03) :583-592